Press releases

ORYZON reports financial results and corporate update for half year ended June 30th, 2026

ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BPD)

ORYZON raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programs

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

ORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia

ORYZON reports financial results and corporate update for quarter ended March 31st, 2026

ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026

ORYZON to participate in upcoming events in May and June

ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax